Altimmune (NASDAQ:ALT) Shares Up 4.4% – What’s Next?

Altimmune, Inc. (NASDAQ:ALT) rose 4.4% during trading on Tuesday . The stock traded as high as $9.23 and last traded at $8.95. Approximately 416,929 shares were traded during trading, a decline of 89% from the average daily volume of 3,845,229 shares. The stock had previously closed at $8.57.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. UBS Group assumed coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Price Performance

The stock has a 50 day moving average price of $7.14 and a 200-day moving average price of $6.95. The stock has a market capitalization of $620.92 million, a P/E ratio of -5.63 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period last year, the firm earned ($0.39) earnings per share. Research analysts predict that Altimmune, Inc. will post -1.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Altimmune by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after acquiring an additional 74,194 shares during the last quarter. Bellevue Group AG lifted its position in shares of Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after purchasing an additional 263,660 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after buying an additional 436,000 shares during the period. Finally, BBR Partners LLC raised its stake in Altimmune by 4.5% in the second quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock worth $2,492,000 after buying an additional 16,271 shares in the last quarter. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.